Navigation Links
Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

ested to study Abbott's Bcl-2 family protein inhibitors, which is an indication of the potential value that ABT-263 might bring to the cancer research field," said John Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "We have built an early stage pipeline that targets the processes that cancers need to survive and we're looking forward to advancing our work in this area."

Presentation highlights include:

-- A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy

of ABT-263 in Subjects With Refractory or Relapsed Lymphoid

Malignancies

-- Reduction in Platelet Counts as a Mechanistic Biomarker and Guide for

Adaptive Dose-escalation in Phase I Studies of the Bcl-2 Family

Inhibitor ABT-263

-- Dynamic Contrast Enhanced MRI (DCE MRI) for Assessment of Effects of

Anti-Angiogenic Therapy: Comparison of the Transfer Constant (Ktrans)

to Blood Flow and Permeability Derived by a Distributed Parameter

Model

-- Relationship of Dose of ABT-869 on Biomarkers of Angiogenesis and

Their Correlation With Pharmacodynamic (PD) Outcome

Study Background and Results

ABT-263

Thirty patients with refractory or relapsed lymphoid malignancies have been enrolled in an ongoing Phase I study evaluating safety, pharmacokinetics and efficacy. Subjects received ABT-263 orally once daily for 14 consecutive days followed by seven days off drug in each cycle of therapy. Results showed that ABT-263 had an acceptable side-effect profile at the seven-dose (10, 20, 40, 80, 160, 225 and 315 mg) cohort levels and showed evidence of anti-tumor activity. Researchers observed 99 percent and 36 percent tumor reduction in two patients with bulky chronic lymphocytic leukemia (CLL). Another patient with bulky CLL/small lymphocytic lymphoma (SLL) experienced a 75 percent reduction and a patient with follicular lymphom
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Abbott to Present at Citi Investment Research Global Health Care Conference
2. Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference
3. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
4. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
5. Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
6. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
7. Abbott Hosts Conference Call for First-Quarter Earnings
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. FDA Approves Abbotts FreeStyle Navigator(R) Continuous Glucose Monitoring System
10. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
11. Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shriners Hospitals for Children® and UK ... current location of Shriners Hospitals for Children - Lexington ... the University of Kentucky Albert B. Chandler Hospital. The ... owned and operated by Shriners Hospitals for Children, and ... and their families well into the future. , “The ...
(Date:10/22/2014)... OR (PRWEB) October 22, 2014 During ... California’s fresh water supply runs dangerously low, Southern Oregon’s ... Southern Oregon’s rivers, despite the lowest mountain snow pack ... in late summer and early autumn.* That was the ... of the new book “Hiking Southern Oregon,” during an ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... By Steven Reinberg ... -- Infants who quickly add weight and length may be ... study suggests. In adults, certain genes have been linked ... promote proportionate gains in fat and lean muscle, the researchers ... be heavier and taller. By ages 2 and 3, however, ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... especially common after the death of a spouse , , ... keep up active social lives as they age may ... finds. , Being socially active may increase feelings ... helping maintain memory, researchers say. Social interaction may also ...
... May 29 PartnerRe Ltd.,(NYSE: PRE ) today ... Benchimol is scheduled to present at the Fox,Pitt-Kelton Cochran ... Opportunities for the Insurers... and the Contrast with,Banks." The ... 6, 2008 from 9 a.m. - 2 p.m. local ...
... published a,new report designed to provide critical strategic ... in the market for diagnostics and treatments,in this ... &,Analysis: Alzheimer,s Disease," is based on in-depth interviews ... involved in ongoing,research., "There is some real ...
... New three-year agreement extends alliance members, access to medical product ... ... systems., LOUDON, Tenn., May 29 Adroit ... by Premier,Purchasing Partners, LP. The new agreement centers on Adroit,s leading,Soft-Temp(R) ...
... Help Firms That Already Offer Insurance to Workers, ERIE, ... than 10,000 uninsured adults in Erie County -- many of ... are on a waiting list,to receive health care coverage -- ... them gain access to health insurance., He said small ...
... DR ),is excited to announce the creation ... division and the errors and omissions (E&O),division., ... leadership of senior vice president and national practice,leader, ... combines all,of Darwin,s health care-related professional liability teams ...
Cached Medicine News:Health News:Active Social Life Helps Keep Aging Mind Sharp 2Health News:Active Social Life Helps Keep Aging Mind Sharp 3Health News:PartnerRe Executive Vice President & Chief Financial Officer Albert Benchimol to Present at the FPK CCW Credit Risk Conference in London on June 6, 2008 2Health News:Cardiovascular Meds May Be Beneficial in Alzheimer's Disease, According to MedPredict Report 2Health News:Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 2Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 3Health News:Governor Rendell Says PA ABC Will Help Low-Wage Small Businesses Pay for Employee Health Coverage 4Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 2Health News:Darwin Announces Creation of New Health Care and Errors and Omissions Divisions 3
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
(Date:10/20/2014)... California , 20 de octubre de 2014 ... en el campo de la pulmonología intervencional, anunció ... Estudio RENEW, casi 3 meses antes de lo ... de exención de dispositivo de investigación (IDE) aprobada ... para el sistema de espiral de reducción de ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... 2 Data presented today,at the Annual Congress ... investigational oral Factor Xa inhibitor DU-176b reduced the ... patients,undergoing elective unilateral hip replacement surgery. There was ... and the,observed bleeding rates were low across the ...
... Stenting Safe and Effective in Patients ... Has Been Open-Heart Surgery, WASHINGTON, Sept. 1 ... patients with very complex coronary,artery disease can safely choose ... open-heart surgery, says The Society for,Cardiovascular Angiography and Interventions ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
... Stealthstation Siremobil Iso-C3D C-Arm imaging system interface ... of mobile C-arm imaging. Combining mobility ... software, the cooperative technologies deliver the most ... 3D imaging is the new standard in ...
... The best of digital mobile imaging ... of,anatomical localization software and instrumentation. Now ... capability to:, Easily Add Visualization ... Dose, Accelerate Intraoperative Decision Making, ...
... the most advanced imaging capabilities into the ... it offers many of the same technologies ... value-oriented platform. Asteion provides the subsecond speed ... scanning, while also supporting everyday, high-resolution scanning ...
... the T.L.I.F. SG Instruments are the ... surgery, offering comprehensive and functionally sound instruments.. ... variety of disc removal and disc preparation ... TLIF procedure. Excellent design, a wide range ...
Medicine Products: